Navigation Links
Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
Date:9/17/2009

CHENGDU, China, Sept. 17 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ('TCM') based in Chengdu, China, today announced that management will hold a conference call to discuss its fiscal 2009 fourth quarter and full year results at 10:30 a.m. ET on Thursday, September 24, 2009.

Interested parties may access the call by dialing +1-877-941-2068 from within the United States, or +1-480-629-9712 if calling internationally. The conference ID is 4161412. It is advisable to dial in approximately 5-10 minutes prior to the start of the call. A replay will be available through October 8, 2009 and can be accessed by dialing +1-800-406-7325 (U.S.), +1-303-590-3030 (Int'l), passcode 4161412.

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at http://www.viavid.net or at the following link: http://viavid.net/dce.aspx?sid=00006A7A . To access the web cast, you will need to have the Windows Media Player on your desktop. For the free download of the Media Player please visit: http://www.microsoft.com/windows/windowsmedia/en/download/default.asp

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in t
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
2. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
3. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
4. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
5. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
6. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
7. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
8. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
9. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
10. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
11. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange ... of health IT to create efficiencies in healthcare information ... Workgroup has developed an issue brief titled, “What ... The HPID Workgroup, a part of WEDI’s Strategic National ... Medicare and Medicaid Services (CMS) to identify common misuse ...
(Date:7/28/2014)... TORONTO , July 28, 2014 /PRNewswire/ -   ... latest group of companies to join its growing portfolio ... hallmarks of Toronto,s JOLT accelerator, ... startups on the roster. Since its ... that have successfully raised  $7.5M of financing. Now at ...
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... , July 28, 2014 Research and ... Particle Size Analysis Market 2014-2018" report to their offering. ... Particle size analysis is a technique used to determine the ... or liquid. It is crucial to analyze the size of ... Therefore, particle size analysis is performed to determine the behavior ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2
... Molecular Origami is ... help illustrate the basics of DNA origami, Harvard’s Wyss Institute has created a Flash-based interactive ... a DNA molecule and then allowing it to self assemble. , ... Boston, Mass. (PRWEB) January 28, 2010 -- Molecular ...
... world,s most powerful supercomputers, scientists at Lawrence Berkeley ... a good match for the future development of ... for green energy production because of their ability ... on "Franklin," a Cray XT4 massively parallel processing ...
... PRINCETON, N.J. , Jan. 27 Covance Inc. (NYSE: ... December 31, 2009 of $0.64 per diluted share.  For ... basis, inclusive of $0.10 per share in gains related to ... in the third quarter.  Excluding the gains on sales and the tax ...
Cached Biology Technology:Wyss Institute Launches "Molecular Origami" Interactive Feature 2Wyss Institute Launches "Molecular Origami" Interactive Feature 3Mismatched alloys are a good match for thermoelectrics 2Mismatched alloys are a good match for thermoelectrics 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 2Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 4Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 5Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 6Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 7Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 8Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 9Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 10Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 11Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 12Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 13Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 14Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 15Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 16Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 17
(Date:7/28/2014)... connections in prairie dogs have uncovered relationships that ... dog communities that may help limit the spread ... The work was done by researchers from North ... Center (NESCent). , "Prairie dogs are increasingly rare ... Jennifer Verdolin, lead author of a paper on ...
(Date:7/27/2014)... to date, researchers from the U.K. provide national, regional, ... virus (HCV). Findings published in Hepatology, a journal of ... indicate that genotype 1 is the most prevalent worldwide, ... reside in East Asia. Genotype 3, at just over ... by genotypes 2, 4, 6, and 5. , ...
(Date:7/27/2014)... scientists at Barts Cancer Institute have found that targeting ... significantly more effective, according to research published in ... Institute, part of Queen Mary University of London, have ... signals the body to repair itself after chemotherapy or ... the researchers removed FAK from blood vessels that grew ...
Breaking Biology News(10 mins):Social network research may boost prairie dog conservation efforts 2Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2
... (Cincinnati, OH) In a study published today in the ... an international team of researchers based in the U.S. and ... lethal, breath holding episodes associated with the neurological disease Rett ... that affects around 1 in 10,000 young girls. On October ...
... Institute in Boston have identified a new type of cell ... animal,s own cells from immune system attack. This ... drive lupus and other autoimmune diseases in which the immune ... The discovery, published in the September 16 issue of ...
... October 4, 2010 Onconova Therapeutics, Inc. announced ... regarding a Special Protocol Assessment (SPA) for the design ... 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), ... the bone marrow. The SPA provides FDA evaluation and ...
Cached Biology News:Research breakthrough hailed on the anniversary of gene discovery 2Discovery of a cell that suppresses the immune system 2Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS 2
... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
... is ideal for high-fidelity amplification of ... as cloning and mutagenesis. High ... enzyme preparation containing recombinant DNA polymerase ... Site5' exonuclease) activity. Platinum Anti-Pfx ...
... PLAU N-term Antibody This antibody is generated ... synthetic peptide selected within aa 50~150 of ... in PBS with 0.09% (W/V) sodium azide. ... G column and eluted out with both ...
...
Biology Products: